Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 1,696 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Asthma (Diagnosis) Clear all
Completed No phase listed Observational Accepts healthy volunteers

Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy

NCT04173442
View directory record Official record
Conditions
Atopic Dermatitis (AD), Asthma
Interventions
dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
581 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 17, 2026, 4:29 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers

NCT03567694
View directory record Official record
Conditions
Asthma
Interventions
HA115, Placebo
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

NCT02555683
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
55
States / cities
Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 17, 2026, 4:29 AM EDT
Active, not recruiting No phase listed Observational

Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology

NCT05757583
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Using Computers to Assist in the Treatment of Asthma in a Pediatric Setting

NCT01312805
View directory record Official record
Conditions
Asthma
Interventions
CHICA Asthma Module, CHICA Control
Other
Lead sponsor
Indiana University
Other
Eligibility
3 Years to 11 Years
Enrollment
2,098 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma

NCT02281357
View directory record Official record
Conditions
Asthma
Interventions
Tralokinumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
New Haven, Connecticut • Clearwater, Florida • St Louis, Missouri + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

NCT03756883
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate and Salmeterol Inhalation Powder, Placebo Inhalation Powder
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2021 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Role of the Isomerase Pin-1 in the Development and Treatment of Asthma

NCT01691612
View directory record Official record
Conditions
Asthma
Interventions
installation of D. pteronyssinus allergens
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2017 · Synced Oct 17, 2026, 4:29 AM EDT
Recruiting Phase 3 Interventional

A Study of Depemokimab in Participants of 6 to 11 Years of Age

NCT07671001
View directory record Official record
Conditions
Asthma
Interventions
Depemokimab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Years to 11 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Mobile, Alabama • Colorado Springs, Colorado • Watertown, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma

NCT01634152
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Tiotropium low dose mcg, Tiotropium high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 11 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
10
States / cities
Rolling Hills Estates, California • Denver, Colorado • North Dartmouth, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

NCT03387852
View directory record Official record
Conditions
Asthma
Interventions
SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
18
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 17, 2026, 4:29 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Molekule for Allergic Rhinitis/Asthma

NCT03627689
View directory record Official record
Conditions
Asthma, Allergic Rhinitis, Allergic Conjunctivitis
Interventions
Active air purifier in respiratory allergies/asthma, Sham air purifier
Other
Lead sponsor
Molekule
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Study of Mepolizumab Safety Syringe in Asthmatics

NCT03021304
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 17, 2026, 4:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterizing Asthma Sputum Elasticity in the UCSF Severe Asthma Research Program

NCT02103348
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants

NCT02495168
View directory record Official record
Conditions
Asthma
Interventions
Generic Budesonide/Formoterol Fumarate Dihydrate, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate), Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Surprise, Arizona • Huntington Beach, California • San Jose, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 1 Interventional

In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics

NCT00836368
View directory record Official record
Conditions
Allergic, Asthmatic, Allergy, Asthma
Interventions
gamma-tocopherol
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma

NCT00783289
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Benralizumab 25 mg, Benralizumab 100 mg, Benralizumab 200 mg
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Encinitas, California • Los Angeles, California • Colorado Springs, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Not applicable Interventional Results available

Telephone-Based Program to Promote Inhaled Corticosteroid Adherence Among Individuals With Asthma

NCT00414817
View directory record Official record
Conditions
Asthma
Interventions
Automated Phone-Based Refill Reminders
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
14,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Honolulu, Hawaii • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 17, 2026, 4:29 AM EDT
Terminated Phase 4 Interventional Results available

Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease

NCT01554488
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea
Interventions
Inhaled Fluticasone Propionate
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.

NCT00392288
View directory record Official record
Conditions
Asthma
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
4 Years to 11 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 17, 2026, 4:29 AM EDT
Active, not recruiting No phase listed Observational

Upper Airway Microbial Development During the First Year of Life

NCT01978288
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
1 Minute to 1 Week
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma

NCT02719379
View directory record Official record
Conditions
Asthma
Interventions
Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)
Biological
Lead sponsor
Rohit Divekar
Other
Eligibility
19 Years to 20 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Not applicable Interventional

Breathing Training for Asthma

NCT00975273
View directory record Official record
Conditions
ASTHMA
Interventions
Capnometry Assisted Respiration Training, Breathing Awareness
Behavioral
Lead sponsor
Southern Methodist University
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 17, 2026, 4:29 AM EDT